Discover how breast cancer precision oncology using a combination therapy improves survival in advanced PIK3CA-mutated cases.

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further ...

Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent ...

Of the total, 161 were given a three-drug combination comprising two targeted drugs – palbociclib, a type of cancer growth blocker, and a new drug called inavolisib, which blocks the activity of ...

AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ...